BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 30353572)

  • 1. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
    Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
    Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
    Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
    Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
    Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
    Ito S; Fukagawa T; Noda M; Hu Q; Nambara S; Shimizu D; Kuroda Y; Eguchi H; Masuda T; Sato T; Katai H; Sasako M; Mimori K
    Ann Surg Oncol; 2018 Nov; 25(12):3755-3763. PubMed ID: 30203407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
    Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
    Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease.
    Kawaguchi A; Akiba J; Kondo R; Sadashima E; Ogasawara S; Naito Y; Kusano H; Sanada S; Muto I; Nakama T; Yano H
    Anticancer Res; 2021 Jan; 41(1):219-226. PubMed ID: 33419816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
    Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
    Eto S; Yoshikawa K; Nishi M; Higashijima J; Tokunaga T; Nakao T; Kashihara H; Takasu C; Iwata T; Shimada M
    Gastric Cancer; 2016 Apr; 19(2):466-471. PubMed ID: 26210691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma.
    Sughayer MA; Dabbagh TZ; Battah AH
    Appl Immunohistochem Mol Morphol; 2020; 28(10):748-754. PubMed ID: 32205740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
    Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
    Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
    Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Zhu X; Zhao P; Zhao J; Liu J; Chen N; Wang J; Shen P; Zeng H
    BMC Cancer; 2019 Apr; 19(1):360. PubMed ID: 30992011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
    Spirina LV; Avgustinovich AV; Afanas'ev SG; Kondakova IV; Volkov MY; Dobrodeev AY; Boronkina AI
    Bull Exp Biol Med; 2020 Nov; 170(1):75-78. PubMed ID: 33231797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.